Progress in direct reprogramming of dopaminergic cell replacement therapy

Parkinson's disease (PD) is a gradual neurodegenerative disease. While drug therapy and surgical treatments have been the primary means of addressing PD, they do not offer a cure, and the risks associated with surgical treatment are high. Recent advances in cell reprogramming have given rise to new prospects for the treatment of Parkinson's disease (PD), with induced pluripotent stem cells (iPSCs), induced dopamine neurons (iDNs), and induced neural stem cells (iNSCs) being created. These cells can potentially be used in the treatment of Parkinson's disease. On the other hand, this article emphasizes the limits of iPSCs and iNSCs in the context of Parkinson's disease treatment, as well as approaches for direct reprogramming of somatic cells into iDNs. The paper will examine the benefits and drawbacks of directly converting somatic cells into iDNs.

Automated summary

Parkinson's disease is a neurodegenerative disease for which current drug and surgical treatments are not curative and are associated with high risks. Recent advances in cell reprogramming offer new prospects for Parkinson's disease treatment, including the creation of iPSCs, iDNs, and iNSCs. However, this article highlights the limitations of using iPSCs and iNSCs for Parkinson's disease treatment and explores the potential of directly reprogramming somatic cells into iDNs.